Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.64 USD | +6.90% | +14.76% | 0.00% |
Apr. 25 | Nasdaq's revenue beats on strong demand for fintech products | RE |
Mar. 26 | Kyverna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 3.75M | Sales 2025 * | 5M | Capitalization | 631M |
---|---|---|---|---|---|
Net income 2024 * | -130M | Net income 2025 * | -199M | EV / Sales 2024 * | 116 x |
Net cash position 2024 * | 197M | Net cash position 2025 * | 142M | EV / Sales 2025 * | 97.8 x |
P/E ratio 2024 * |
-4.6
x | P/E ratio 2025 * |
-3.7
x | Employees | 96 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.27% |
1 day | +6.90% | ||
1 week | +14.76% | ||
Current month | +3.47% | ||
1 month | -31.56% | ||
3 months | -47.59% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Maag
CEO | Chief Executive Officer | 56 | 22-10-12 |
Ryan Jones
DFI | Director of Finance/CFO | 36 | 17-12-31 |
Dominic Borie
CTO | Chief Tech/Sci/R&D Officer | 61 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 18-08-31 |
Ian Clark
CHM | Chairman | 62 | 21-09-14 |
Dan Spiegelman
BRD | Director/Board Member | 65 | 21-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 15.68 | +7.18% | 45 517 |
24-05-13 | 14.63 | +4.50% | 480,075 |
24-05-10 | 14 | -4.11% | 217,579 |
24-05-09 | 14.6 | +15.32% | 280,449 |
24-05-08 | 12.66 | -7.25% | 423,239 |
Delayed Quote Nasdaq, May 14, 2024 at 10:54 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 631M | |
+29.76% | 48.16B | |
-0.74% | 41.73B | |
+43.85% | 41.03B | |
-5.31% | 28.77B | |
+10.56% | 25.59B | |
-22.52% | 18.96B | |
+8.85% | 12.92B | |
+28.57% | 12.03B | |
-2.51% | 11.77B |
- Stock Market
- Equities
- KYTX Stock